한글목차

양극성 장애 치료제의 동향과 예측

세계의 양극성 장애 치료제 시장은 2024년부터 2030년까지 연평균 복합 성장률(CAGR) 3.7%로 성장할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 정신 건강에 대한 인식 증가와 양극성 장애의 유병률 증가입니다. 세계의 양극성 장애 치료제 시장의 미래는 경구약 시장과 비경구약 시장에 기회가 있고 유망시되고 있습니다.

양극성 장애 치료제의 부문별 추이

본 조사에서는 약제 클래스별, 투여경로별, 작용기전별, 지역별 양극성장애치료제의 세계 시장 예측을 제공합니다.

양극성 장애 치료제 시장 인사이트

Lucintel사는 정신병 증상의 증례가 증가하고 있기 때문에 예측 기간 동안에도 항정신병약이 최대 부문인 것을 계속할 것으로 예측했습니다.

이 시장에서 경구 약물은 투여 유연성과 비용 효율성이 높기 때문에 최대 부문으로 계속 될 것으로 보입니다.

북미는 양극성 장애의 유병률이 증가함에 따라 예측 기간 동안 가장 규모가 큰 지역이 될 것입니다.

FAQ

Q1. 시장의 성장 예측은 :

A1. 세계 양극성 장애 치료제 시장은 2024년부터 2030년까지 연평균 복합 성장률(CAGR) 3.7%로 성장할 것으로 예상됩니다.

Q2. 시장 성장에 영향을 미치는 주요 촉진요인은 :

A2. 이 시장의 주요 촉진요인은 정신 건강에 대한 인식 증가와 양극성 장애의 유병률의 상승입니다.

Q3. 시장의 주요 부문은 :

A3. 양극성 장애 치료제 시장의 미래는 경구약 시장과 비경구약 시장에 기회가 있고 유망합니다.

Q4. 시장의 주요 기업은 :

A4. 양극성 장애 치료제 주요 기업은 다음과 같습니다.

• GlaxoSmithKline
• Pfizer
• Eli Lily
• AbbVie
• Otsuka Holdings
• AstraZeneca
• Novartis

Q5. 앞으로 가장 큰 시장 부문은 :

A5.Lucintel은 정신병 증상의 증례가 증가하고 있기 때문에 예측 기간 동안 항정신병 약물이 최대 부문으로 계속 될 것으로 예측했습니다.

Q6. 시장에서 향후 5년간 최대가 될 것으로 예상되는 지역은:

A6. 양극성 장애의 유병률이 증가함에 따라 북미는 예측 기간 동안 가장 규모가 큰 지역으로 남아 있습니다.

Q7. 보고서 사용자 정의는 가능한가?

A7. 그렇습니다, Lucintel는 추가 비용 없이 10% 주문을 받아서 만듭니다.

목차

제1장 주요 요약

제2장 세계의 양극성 장애 치료제 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 양극성 장애 치료제 세계 시장 동향(2018-2023년)과 예측(2024-2030년)
• 약제 클래스별 세계의 양극성 장애 치료제 시장
  • 기분 안정제
  • 항경련제
  • 항정신병약
  • 항우울제
  • 항불안제
• 투여 경로별 세계의 양극성 장애 치료제 시장
  • 경구약
  • 비경구약
  • 기타
• 작용기전별 양극성 장애 치료제 세계 시장
  • 선택적 세로토닌 재 흡수 억제제
  • 세로토닌 노르 에피네프린 재 흡수 억제제
  • 삼환계 항우울제
  • 베타 차단제
  • 기타

제4장 지역별 시장 동향과 예측 분석(2018-2023년)

• 지역별 세계 양극성 장애 치료제 시장
• 북미의 양극성 장애 치료제 시장
• 유럽의 양극성 장애 치료제 시장
• 아시아태평양의 양극성 장애 치료제 시장
• 기타 지역 양극성 장애 치료제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 업무 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 약제 클래스별 세계의 양극성 장애 치료제 시장의 성장 기회
  • 투여 경로별 세계의 양극성 장애 치료제 시장의 성장 기회
  • 작용기전별 세계의 양극성 장애 치료제 시장의 성장 기회
  • 지역별 세계의 양극성 장애 치료제 시장의 성장 기회
• 세계의 양극성 장애 치료제 시장에서의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 양극성 장애 치료제 시장의 세계 용량 확대
  • 세계의 양극성 장애 치료제 시장에서의 합병, 인수, 합작 사업
  • 인증 및 라이선싱

제7장 주요 기업의 기업 프로파일

• GlaxoSmithKline
• Pfizer
• Eli Lily
• AbbVie
• Otsuka Holdings
• AstraZeneca
• Novartis

영문목차

Bipolar Disorder and Treatment Trends and Forecast

The future of the global bipolar disorder and treatment market looks promising with opportunities in the oral and parenteral markets. The global bipolar disorder and treatment market is expected to grow with a CAGR of 3.7% from 2024 to 2030. The major drivers for this market are rising awareness on mental health and rising prevalence of bipolar disorders.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Bipolar Disorder and Treatment by Segment

The study includes a forecast for the global bipolar disorder and treatment by drug class, route of administration, mechanism of action, and region.

Bipolar Disorder and Treatment Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

• Mood Stabilizer
• Anticonvulsants
• Anti-Psychotic Drugs
• Anti-Depressant Drugs
• Anti-Anxiety Drugs

Bipolar Disorder and Treatment Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

• Oral
• Parenteral
• Others

Bipolar Disorder and Treatment Market by Mechanism of Action [Shipment Analysis by Value from 2018 to 2030]:

• Selective Serotonin Reuptake Inhibitor
• Serotonin Norepinephrine Reuptake Inhibitor
• Tricyclic Antidepressant Drug
• Beta Blockers
• Others

Bipolar Disorder and Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Bipolar Disorder and Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bipolar disorder and treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bipolar disorder and treatment companies profiled in this report include-

• GlaxoSmithKline
• Pfizer
• Eli Lily
• AbbVie
• Otsuka Holdings
• AstraZeneca
• Novartis

Bipolar Disorder and Treatment Market Insights

Lucintel forecasts that anti-psychotic drug will remain the largest segment over the forecast period due to growing cases of psychotic symptoms.

Within this market, oral will remain the largest segment due to its enhanced dosing flexibility and cost-effectiveness.

North America will remain the largest region over the forecast period due to rising prevalence of bipolar disorders.

Features of the Global Bipolar Disorder and Treatment Market

Market Size Estimates: Bipolar disorder and treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Bipolar disorder and treatment market size by drug class, route of administration, mechanism of action, and region in terms of value ($B).

Regional Analysis: Bipolar disorder and treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug class, route of administration, mechanism of action, and regions for the bipolar disorder and treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bipolar disorder and treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for bipolar disorder and treatment market?

Answer: The global bipolar disorder and treatment market is expected to grow with a CAGR of 3.7% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the bipolar disorder and treatment market?

Answer: The major drivers for this market are rising awareness on mental health and rising prevalence of bipolar disorders.

Q3. What are the major segments for bipolar disorder and treatment market?

Answer: The future of the bipolar disorder and treatment market looks promising with opportunities in the oral and parenteral markets.

Q4. Who are the key bipolar disorder and treatment market companies?

Answer: Some of the key bipolar disorder and treatment companies are as follows:

• GlaxoSmithKline
• Pfizer
• Eli Lily
• AbbVie
• Otsuka Holdings
• AstraZeneca
• Novartis

Q5. Which bipolar disorder and treatment market segment will be the largest in future?

Answer: Lucintel forecasts that anti-psychotic drug will remain the largest segment over the forecast period due to growing cases of psychotic symptoms.

Q6. In bipolar disorder and treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to rising prevalence of bipolar disorders.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the bipolar disorder and treatment market by drug class (mood stabilizer, anticonvulsants, anti-psychotic drugs, anti-depressant drugs, and anti-anxiety drugs), route of administration (oral, parenteral, and others), mechanism of action (selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, tricyclic antidepressant drug, beta blockers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Bipolar Disorder and Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Bipolar Disorder and Treatment Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Bipolar Disorder and Treatment Market by Drug Class
  • 3.3.1: Mood Stabilizer
  • 3.3.2: Anticonvulsants
  • 3.3.3: Anti-Psychotic Drugs
  • 3.3.4: Anti-Depressant Drugs
  • 3.3.5: Anti-Anxiety Drugs
• 3.4: Global Bipolar Disorder and Treatment Market by Route of Administration
  • 3.4.1: Oral
  • 3.4.2: Parenteral
  • 3.4.3: Others
• 3.5: Global Bipolar Disorder and Treatment Market by Mechanism of Action
  • 3.5.1: Selective Serotonin Reuptake Inhibitor
  • 3.5.2: Serotonin Norepinephrine Reuptake Inhibitor
  • 3.5.3: Tricyclic Antidepressant Drug
  • 3.5.4: Beta Blockers
  • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Bipolar Disorder and Treatment Market by Region
• 4.2: North American Bipolar Disorder and Treatment Market
  • 4.2.1: North American Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
  • 4.2.2: North American Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others
• 4.3: European Bipolar Disorder and Treatment Market
  • 4.3.1: European Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
  • 4.3.2: European Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others
• 4.4: APAC Bipolar Disorder and Treatment Market
  • 4.4.1: APAC Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
  • 4.4.2: APAC Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others
• 4.5: ROW Bipolar Disorder and Treatment Market
  • 4.5.1: ROW Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
  • 4.5.2: ROW Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Drug Class
  • 6.1.2: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Route of Administration
  • 6.1.3: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Mechanism of Action
  • 6.1.4: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Region
• 6.2: Emerging Trends in the Global Bipolar Disorder and Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Bipolar Disorder and Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Bipolar Disorder and Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GlaxoSmithKline
• 7.2: Pfizer
• 7.3: Eli Lily
• 7.4: AbbVie
• 7.5: Otsuka Holdings
• 7.6: AstraZeneca
• 7.7: Novartis